ClinicalTrials.gg
WithdrawnNCT05251376Updated Jan 19, 2023

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

A Phase 1 interventional study of Levomethadone HCl and Methadone in Opioid Use Disorder, Moderate, sponsored by Lyndra Inc.. Withdrawn. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Lyndra Inc. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.

Enrollment
18th of 19
0 · median 68
Started
2022
the only one that year
Phase 1
3 of 19
1 open now
Registered
14th of 19
by date
Lead sponsor
1 of 19
Lyndra Inc.

Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1, and was the 14th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing methadone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy

Read the detailed description

Lyndra Therapeutics is currently developing extended release (ER) capsules for weekly administration across therapeutic areas with certain medications for which consistent pharmacokinetics (PK) or enhanced adherence may translate to improved efficacy, and possibly better safety. LYN-014 ER capsules are intended to provide comparable levomethadone exposure to daily treatment with racemic methadone for people with opioid use disorder (OUD). Compared to daily methadone dosing, LYN-014 could provide greater accessibility to methadone therapy and reduce the time devoted to obtaining medication the number of visits to methadone clinics, and thus reduce the stigma associated with methadone treatment, improve the quality of life for patients, and reduce the potential for diversion. This single dose study will evaluate the safety, tolerability, and PK of LYN-014 in individuals with OUD who are stable on daily methadone treatment. Data from this study will inform formulation optimization and dose selection for further development.

03

Conditions studied

  • Opioid Use Disorder, Moderate
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in the study, individuals must meet all the following inclusion criteria at Screening (and at other timepoints, where specified):

Male or female aged ≥18 and ≤59 years. of ≥18 kg/m2 and ≤33 kg/m2. Moderate or severe OUD according to the criteria. Clinically stable (for at least 6 months) on oral daily methadone therapy at a dose of 80 to 100 mg and have been taking the same dose for at least 3 months, and are stably engaged in a methadone program, confirmed by a methadone provider and defined as (1) demonstrates evidence of regular attendance, (2) has not had problems with missed visits, and (3) consistently demonstrates drug-negative urine samples (except for cannabis).

Agree to provide the study site with contact information for the clinic where they get methadone and agree that a study physician can contact the clinician providing methadone to confirm appropriateness for study participation and to manage their transition into the study and from the study back to their opioid treatment program.

Able to read and understand study procedures and provide written before the initiation of any protocol-specific procedures.

Willing to comply with all protocol-specified procedures and availability for the duration of the study (e.g., participant is not aware of any emergent life-changes or potential family emergencies that would interfere with a 40+ day inpatient stay).

Exclusion criteria

Exclusion Criteria:

To be eligible to participate in the study, individuals must not meet any of the following exclusion criteria at Screening (and at other timepoints, where specified):

  1. Known esophageal or GI disease, including but not limited to:

a. Known strictures such as esophageal web, pyloric stenosis, small intestinal stricture, or individuals with high risk of stricture, ie, Crohn's disease b. Diagnosis of a condition known to elevate or lower gastric pH, eg, achlorhydria or hypochlorhydria c. Prior small or large bowel obstructions or varices d. Prior abdominal or upper GI surgery (prior uncomplicated laparoscopic procedures are permitted) e. History of dysphagia or aspiration in the last 5 years f. History of an esophageal motility disorder or undergoing treatment for a gastric motility disorder g. Significant history of diarrhea or constipation (non-methadone related) within 3 months of Screening h. Fewer than 3 bowel movements per week, on average i. Multiple episodes of abdominal pain in the prior 3 months j. Moderate or severe dysmenorrhea or menorrhagia (with use of pain medication) in the prior 3 months.

k. History of gastroparesis, rumination, gastritis, H.pylori gastritis, or irritable bowel syndrome l. History compatible with acid reflux (heartburn, regurgitation, dysphagia, chest pain, water brash, globus sensation, odynophagia) m. Medical history compatible with Achlorhydria (i.e., history of autoimmune gastritis, pernicious anemia, H. plylori infection, partial gastrectomy).

  1. History of moderate to severe Acid Reflux Disease or a score of ≥2 on the Acid Reflux Severity Scale (ARSS), indicating moderate to severe symptoms. The ARSS scale is as follows:

    None = 0 no symptoms Mild = 1 awareness of symptom, but easily tolerated Moderate = 2 discomfort sufficient to cause interference with normal activities Severe = 3 incapacitating, with inability to perform normal activities.

  2. Individuals with PILL 5 swallowing questionnaire score of 5 or greater.
  3. Medical history or current diagnoses indicating the presence of any of the following conditions:

    1. Presence of an uncontrolled, unstable, or clinically significant medical condition, mental impairment, or psychiatric disease (e.g., schizophrenia, bipolar, major depression, or borderline personality disorder) that could put the subject at risk because of participation in the study, interfere with the subject's ability to participate in the study or influence the interpretation of safety or PK evaluations
    2. History of a major cardiovascular event (myocardial infarction, cardiac surgery or revascularization, unstable angina, stroke, or ) or a hospitalization for heart failure within 6 months of Screening
    3. Presence of Long Syndrome
    4. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of Screening, in the opinion of the Sponsor/designee or Principal Investigator
    5. Known status, including individuals who have undergone organ transplantation, on immunosuppression for an immune mediated disease, or are positive for
    6. Positive test for active at Screening, unless hepatitis B infection has been resolved for ≥1 year
    7. Donated more than 250 mL of blood within 4 weeks of Screening
    8. Difficulties with venipuncture/cannulation, including difficulty accessing veins for blood sampling and/or history of coagulopathy or endocarditis
    9. Suicidal ideation associated with actual intent and a method or plan in the past 6 months, as measured by the C-SSRS (i.e., "Yes" answers on items 4 or 5) at Screening or Day 1, or has a history of suicide attempt within the last 2 years
    10. Chronic pain that requires chronic opioid treatment
    11. Active SARS-CoV-2 infection, as defined in the site-specific COVID 19 Risk Mitigation Plan
    12. History of pernicious anemia
    13. History of advanced cirrhosis
  4. Use of the below in the 2 weeks before enrollment:

    1. Proton pump inhibitors and H2 blockers
    2. Prokinetics
    3. Grapefruit juice, blood oranges, Seville (bitter) oranges, and star fruit
    4. Medications that may interfere with the absorption, metabolism, or excretion of methadone (see Appendix 18.1)
    5. Medications that have a known risk of Torsades des Pointes (see Appendix 18.2)
    6. Concomitant medications, natural remedies, supplements, or vitamins that are associated with changes to gastric motility or pH. Use of antacids is permissible, except for within 2 hours of dosing with LYN 014
    7. Benzodiazepines except for treatment of insomnia (short/medium acting benzodiazepines used occasionally (1 or 2 times per week)
    8. Hormonal
  5. Use of blood products within 3 months of Screening.
  6. Medical history or current diagnosis of chronic obstructive pulmonary disorder, restrictive lung disease, asthma, or any condition that could contribute to respiratory distress during study participation.
  7. Clinically significant abnormal safety (e.g., physical examination, vital signs) or safety laboratory assessments at Screening, specifically:

    1. Presence of a clinically significant abnormal laboratory result on blood or urine safety tests
    2. Anemia ( below lower limit of normal reference range and considered to be clinically significant)
    3. or aspartate aminotransferase ≥3.0 × or total ≥1.5 × upper limit of normal
    4. Moderate or severe renal insufficiency ( \<60 mL/min as determined using the formula)
    5. Heart rate \<60 beats per minute (bpm)
    6. Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
    7. (hemoglobin A1c; HbA1c) ≥6.5 mmol/L
    8. Thrombocytopenia ( \<150 × 109/L) or bleeding diathesis (International Normalization Ratio > 1.4)
    9. Positive fecal occult blood test (FOBT) at Screening
  8. The following specified patterns of substance use:

    1. Concomitant substance use disorder other than OUD, caffeine use disorder, or nicotine use disorder
    2. Positive urine drug screen for cocaine, amphetamine, methamphetamine, barbiturates, propoxyphene, phencyclidine, or buprenorphine
    3. Cannabis use disorder
    4. Positive ethanol breathalyzer result
  9. Women of and men, who are unwilling to use acceptable means of contraception through the EOS. For clarity, women who are at least 1 year post menopausal are considered not of childbearing potential and can be included in the study. Acceptable means of contraception include:

    1. Individuals who have been surgically sterilized
    2. Females of childbearing potential: diaphragm, contraceptive sponge, or intrauterine device in use before enrollment, in combination with use of a condom for their male partners
    3. Males: condom in combination with any of the above means of contraception for their female partners
    4. All individuals: abstinence is only acceptable if a subject chooses not to be sexually active
  10. Individuals who are nursing or have a positive or indeterminate pregnancy test at Screening (serum test) or Day 1 (urine test).
  11. Use of any experimental agent within 3 months or 5 half lives of Screening, whichever is longer.
  12. Employees or immediate family members of employees of the site, Sponsor, or study related vendors.
  13. History of a serious allergic or reaction to LYN 014 components or any components of morphine sulfate or ancillary medications.
  14. History of X ray, computed tomography scan or angiogram of the abdomen within 1 year of Screening.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LYN-014 Extended-Release Levomethadone HCl

    Extended-release levomethadone HCl 187 mg administered orally once on Day 8 of the study.

    Drug: Levomethadone HCl · Drug: Methadone · Drug: Morphine Sulfate · Diagnostic Test: x-ray · Diagnostic Test: blood tests

Interventions

  • DrugLevomethadone HCl

    One dose given orally on Day 8 of the study.

    Also known as: extended-release levomethadone

  • Daily usual oral dose given on Day 1 and Day 2 of the study.

    Also known as: oral methadone

  • Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.

    Also known as: morphine

  • Diagnostic testx-ray

    Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.

    Also known as: abdominal x-ray

  • Diagnostic testblood tests

    Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.

    Also known as: Blood draws, lab tests

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of the LYN-014 dose when administered orally as a single dose

    Incidence of treatment-emergent adverse events and serious adverse events

    Time frame: 52 days

  2. To characterize the PK of levomethadone for LYN-014 (Cmin)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate Cmin (minimum concentration)

    Time frame: 52 days

  3. To characterize the PK of levomethadone for LYN-014 (Tmin)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate Tmin (Time at minimum concentration)

    Time frame: 52 days

  4. To characterize the PK of levomethadone for LYN-014 (Cmax)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate Cmax (maximum concentration)

    Time frame: 52 days

  5. To characterize the PK of levomethadone for LYN-014 (Tmax)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate Tmax (Time at maximum concentration)

    Time frame: 52 days

  6. To characterize the PK of levomethadone for LYN-014 (Kel)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate Kel (Elimination Rate Constant)

    Time frame: 52 days

  7. To characterize the PK of levomethadone for LYN-014 (AUC0-20)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-20 (Area under the curve from 0-24 hours)

    Time frame: 52 days

  8. To characterize the PK of levomethadone for LYN-014 (AUC0-t)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-t (Area under the curve from 0 to t hours)

    Time frame: 52 days

  9. To characterize the PK of levomethadone for LYN-014 (AUC0-∞t)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-∞t (Area under the curve from 0 to infinity)

    Time frame: 52 days

  10. To characterize the PK of levomethadone for LYN-014 (C last)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate C last (Last measurable concentration)

    Time frame: 52 days

  11. To characterize the PK of levomethadone for LYN-014 (T last)

    PK of levomethadone after oral administration of LYN-014, to include where possible and appropriate T last (Time at last measurable concentration)

    Time frame: 52 days

Secondary outcomes

  1. To characterize the PK of methadone enantiomers after methadone dosing (Cmin)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Cmin (Minimum Concentration)

    Time frame: 52 days

  2. To characterize the PK of methadone enantiomers after methadone dosing (Tmin)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Tmin (Time at minimum concentration)

    Time frame: 52 days

  3. To characterize the PK of methadone enantiomers after methadone dosing (Cmax)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Cmax (Maximum concentration)

    Time frame: 52 days

  4. To characterize the PK of methadone enantiomers after methadone dosing (Tmax)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Tmax (Time at maximum concentration)

    Time frame: 52 days

  5. To characterize the PK of methadone enantiomers after methadone dosing (Kel)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Kel (Elimination Rate Constant)

    Time frame: 52 days

  6. To characterize the PK of methadone enantiomers after methadone dosing (AUC0-24)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate AUC0-24 (Area under the curve from 0 to 24 hours)

    Time frame: 52 days

  7. To characterize the PK of methadone enantiomers after methadone dosing (AUC0-t)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate AUC0-t (Area under the curve from 0 to t hours)

    Time frame: 52 days

  8. To characterize the PK of methadone enantiomers after methadone dosing (AUC0-∞)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate AUC0-∞ (Area under the curve from 0 to infinity)

    Time frame: 52 days

  9. To characterize the PK of methadone enantiomers after methadone dosing (Clast)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Clast (Last measurable concentration)

    Time frame: 52 days

  10. To characterize the PK of methadone enantiomers after methadone dosing (Tlast)

    PK of levomethadone and dextromethadone (S-enantiomer of methadone) after oral administration of methadone, to include where possible and appropriate Tlast (Time at last measurable concentration)

    Time frame: 52 days

  11. To characterize the PK of LYN 014 compared with that of daily methadone Cmax Extended Release to Cmax Immediate Release

    Compare the PK ratio of Cmax (maximum concentration) ER (LYN-014) to Cmax (maximum concentration) IR (methadone).

    Time frame: 52 days

  12. To evaluate possible conversion of Levomethadone to Dextromethadone (Cmin)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Cmin (minimum concentration)

    Time frame: 52 days

  13. To evaluate possible conversion of Levomethadone to Dextromethadone (Tmin)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Tmin (Time at minimum concentration)

    Time frame: 52 days

  14. To evaluate possible conversion of Levomethadone to Dextromethadone (Cmax)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Cmax (Maximum concentration)

    Time frame: 52 days

  15. To evaluate possible conversion of Levomethadone to Dextromethadone (Tmax)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Tmax (Time at maximum concentration)

    Time frame: 52 days

  16. To evaluate possible conversion of Levomethadone to Dextromethadone (Kel)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Kel (elimination rate constant)

    Time frame: 52 days

  17. To evaluate possible conversion of Levomethadone to Dextromethadone (AUC0-24)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-24 (Area under the curve from 0 to 24 hours)

    Time frame: 52 days

  18. To evaluate possible conversion of Levomethadone to Dextromethadone (AUC0-t)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-t (Area under the curve from 0 to t hours)

    Time frame: 52 days

  19. To evaluate possible conversion of Levomethadone to Dextromethadone (AUC0-∞)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate AUC0-∞ (Area under the curve from 0 to infinity)

    Time frame: 52 days

  20. To evaluate possible conversion of Levomethadone to Dextromethadone (Clast)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Clast (last measurable concentration)

    Time frame: 52 days

  21. To evaluate possible conversion of Levomethadone to Dextromethadone (Tlast)

    PK of dextromethadone after oral administration of LYN-014, to include where possible and appropriate Tlast (Time at last measurable concentration)

    Time frame: 52 days

  22. To assess gastrointestinal (GI) transit and exit properties of LYN 014.

    GI transit and exit properties of LYN 014 assessed by X ray imaging and fecal recovery.

    Time frame: 52 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Dec 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 22, 2022
StartActual
Feb 28, 2022
Primary completionActual
Dec 19, 2022
CompletionActual
Dec 19, 2022
Last update
Jan 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05251376
Lead sponsor
Lyndra Inc.
Responsible party
Sponsor
First posted
Feb 22, 2022
Start date
Feb 28, 2022
Primary completion
Dec 19, 2022
Completion
Dec 19, 2022
Last update
Jan 19, 2023

Study contacts

Richard Scranton, MD, MPH
principal investigator · Lyndra Therapeutics INC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion